Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 25, 2016

View Archived Issues

EDP-305 is a novel potent FXR agonist with promising efficacy in vitro and in vivo

AstraZeneca patents FLAP and leukotriene synthesis inhibitors

Mutabilis discloses beta-lactamase inhibitors

Entyvio receives positive reimbursement recommendation in Canada

Hepatitis C candidate EDP-494 shows promise in early clinical trial

Novel dexamethasone prodrug ZSJ-0228 has lower systemic exposure, improved safety

Shionogi signs license agreement with Tokushima University for novel type A2 Botulinum toxin

Canadian Stem Cell Network announces funding to support stem cell research

First patient given allogeneic adipose tissue-derived multilineage progenitor cells in phase I study

Kymab raises Series C financing to advance antibody pipeline

NVIDIA Foundation awards grant to TGen to support technology efforts in cancer

Novel BTK mutation may cause ibrutinib resistance

Anavex offers 41-week update from phase IIa study of ANAVEX 2-73 in mild to moderate Alzheimer's

Lysyl oxidase homolog 2 identified as a therapeutic target for liver fibrosis

Verseon describes novel direct thrombin inhibitor VE-1902

Janssen-Cilag seeks approval of guselkumab in Europe

FN1 is significantly upregulated in ASM vs. ISM

AiCuris conducting new preclinical study of AIC-649 with support from NIAID

GlaxoSmithKline begins phase III program for daprodustat in anemia associated with CKD

Researchers test new highly potent FXR agonist, EP-024297

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...